Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022
29 avr. 2022 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference
06 avr. 2022 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
10 mars 2022 16h05 HE
|
Clearside Biomedical, Inc.
- XIPERE® -Related Milestones Generated $20 Million in Non-Dilutive Funding in Q4 2021 - - Continued Progress in CLS-AX OASIS Wet AMD Phase 1/2a Trial with Cohort 3 Results Expected Mid-2022 - -...
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
03 mars 2022 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022
01 mars 2022 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Clearside Biomedical to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 10, 2022
25 févr. 2022 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference
14 févr. 2022 16h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference on February 12, 2022
02 févr. 2022 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
21 déc. 2021 07h05 HE
|
Clearside Biomedical, Inc.
- Suprachoroidal Injection of CLS-AX 0.1 mg Dose Well-Tolerated in Cohort 2 with No Treatment Related Adverse Events –- Consistent Safety Profile Observed in Cohorts 1 and 2 Supports Advancement to...
Clearside Biomedical Added to the Nasdaq Biotechnology Index
13 déc. 2021 16h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...